Intranasal Dexmedetomidine-esketamine Administration and Postoperative Pain in Pediatric Patients

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age3-7
SponsorPeking University First Hospital

About this trial

Postoperative pain after adenoid and tonsil surgery is significant, with approximately 75% of pediatric patients experiencing severe postoperative pain. Currently, there is a lack of clinical strategies to safely and effectively manage postoperative pain in children undergoing adenoid and tonsil surgery. Dexmedetomidine and esketamine can achieve appropriate sedation levels and alleviate postoperative pain when used in children. Both drugs can be administered intranasally, and their pharmacological effects complement each other, reducing side effects. This study aims to investigate whether intranasal administration of dexmedetomidine-esketamine combination can improve postoperative analgesia in children undergoing adenoid and tonsil surgery.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Aged 3-7 years old.

Scheduled to undergo adenoidectomy and/or tonsillectomy under general anesthesia.

Provides written informed consent by the guardian.

Disqualifiers

Unsuitable for intranasal administration due to nasal diseases (such as rhinitis, nasal polyps, or any condition causing nasal congestion).

Clearly diagnosed cardiovascular and respiratory diseases.

Communication barriers due to delayed neurological development or visual or hearing impairments.

Traumatic brain injury or neurosurgery.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Intranasal dexmedetomidine-esketamine

    Drug

    A mixture of dexmedetomidine-esketamine combination will administered intranasally after anesthesia induction.

  • Intranasal placebo (normal saline)

    Drug

    Placebo (normal saline) will administered intranasally after anesthesia induction.

Treatment groups

160 Participants
are divided into 2 treatment groups
Group A: Intervention groupExperimental treatment 1 intervention
Group B: Control groupPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Area under curve of pain intensity within 48 hours after surgery

Pain intensity will be assessed with the Face, Legs, Activity, Cry, Consolability scale (FLACC; scores range from 0 to 10, with higher scores indicating more severe pain intensity) at 10, 20, an 30 minutes after entering the post-anesthesia care unit (PACU), at 3 and 6 hours after surgery, and then twice daily (8:00-10:00 am, 6:00-8:00 pm) until 48 hours after surgery.

Time frame
Up to 48 hours after surgery

Secondary outcomes

1

Sleep quality during the first three nights after surgery

Sleep quality will be assessed by the guardians using the numeric rating scale (NRS; a 0-10 scale where 0=the best sleep and 10=the worst sleep) in the first three morning (8:00-10:00 am) after surgery.

Time frame
Up to three days after surgery
2

Cumulative consumption of analgesics within 48 hours

Cumulative consumption of analgesics within 48 hours after surgery.

Time frame
Up to 48 hours after surgery

Other outcomes

1

Time to extubation after surgery

Time to extubation at the end of surgery.

Time frame
Up to 2 hours after surgery
2

Length of stay in PACU

Length of stay in PACU after surgery.

Time frame
Up to 24 hours after surgery
3

Incidence of adverse events during PACU stay

Adverse events are defined as any events that required intervention during PACU stay, including laryngospasm, bronchospasm, airway obstruction, nausea and vomiting, desaturation (pulse oxygen saturation \<90%), bradycardia (heart rate \<60 beats per minute), bleeding, and others.

Time frame
Up to 24 hours after surgery
4

Length of stay in hospital after surgery

Length of stay in hospital after surgery.

Time frame
Up to 30 days after surgery

Sponsors and contacts

Click on the lead sponsor to view all of their trials.